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Background: Chemokine-driven migration of inflam-
matory cells has been implicated in the pathogenesis
of atherosclerotic conditions including peripheral
arterial disease (PAD). Monocyte chemoattractant
protein-1 (MCP-1) is elevated in patients with cor-
onary artery disease and in hypertensive patients.
This study therefore investigated MCP-1 in patients
with PAD.
Methods: Serum MCP-1 was determined by enzyme-
linked immunosorbent assay in 36 healthy, control
subjects and in 19 patients with PAD. Statistical
analysis utilised the Mann 
/Whitney test and Spear-
man correlation (p B/0.05).
Results: MCP-1 (pg/ml) was increased in patients
compared with in controls (mean9 /standard error of
the mean: PAD group, 7489 /60; control group, 4599 /
27; p/0.0001). MCP-1 levels tended to decrease with
progressing disease. From atherosclerosis risk fac-
tors, diabetes inclined to increase MCP-1 levels;
hypertension had no effect. Serum MCP-1 correlated
with cholesterol, triglycerides, low-density lipopro-
tein but not high-density lipoprotein.
Conclusion: Elevation of MCP-1 in the circulation of
PAD patients shown in the present pilot study
implicates this CC chemokine ligand 2 in inflamma-
tory processes contributing to PAD clinical sympto-
matology. Further investigations are necessary to
evaluate whether MCP-1 can be used as a potential
marker of peripheral arterial disease follow-up and/
or prognosis.
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Introduction
Chemokines (chemotactic cytokines) are low mole-
cular weight polypeptides that, besides other func-
tions, exert potent chemotactic and activating effects
on specific leukocyte populations.
1 Recently, there
has been growing interest in applications of chemo-
kine biology into clinic including cardiovascular
disease, namely atherosclerosis.
2 CC chemokine
ligand 2, more widely known as monocyte chemo-
attractant protein-1 (MCP-1), is a potent mononuclear
cell attractant.
3 It has been previously implicated in
the atherosclerosis development by mediating the
influx of monocytes /macrophages into early athero-
sclerotic lesions.
4 Recently, elevation of MCP-1
has been shown in patients with patients with
coronary artery disease
5 and in hypertensive pa-
tients.
6
Ischaemic heart disease is the most common form
of atherosclerosis. There are, however, also other
types of atherosclerosis such as thrombosis of other
major vessels, ischaemic renal disease or peripheral
arterial disease (PAD).
7 PAD, also called artheritis
obliterans, is characterised by generalised localisation
of atherosclerotic lesions in the main arteries of the
lower extremities, resulting in claudication symptom-
atology.
8
To investigate whether MCP-1 is implicated also in
the development of peripheral arterial disease, we
have conducted the present pilot study, in which
chemokine serum levels were determined by a
sensitive immunoassay and comparisons made be-
tween control subjects and patients with PAD. MCP-1
levels were further compared between two patient
subgroups with distinct disease course. The effect of
known risk factors of atherosclerosis such as smok-
ing, hypertension diabetes mellitus on MCP-1 serum
levels was explored, as well as the relationship
between the chemokine and lipid profile markers.
Materials and methods
Study population
MCP-1 protein levels were investigated in peripheral
blood samples obtained from the cubital vein of 36
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39control subjects (age [mean9 /standard deviation],
32.49 /13.7; 27 males, nine females; 21 non-smokers,
15 smokers) and of 19 patients with PAD (age, 59.09 /
10.9 years; 18 males, one female; 13 non-smokers, six
smokers). The diagnosis of PAD was based on
characteristic clinical features together with typical
results of angiography and non-invasive Doppler
pressure assessment.
8 The disease course was as-
sessed according to Fontain (see, for example,
Reference
9), exploiting the claudication distance
(cd): stage 2a, cd /400 m (n /5); stage 2b,
cd /200 /400 m (n /8); stage 2c, cdB/200 m
(n /3); and stage 3, ischaemic pain at rest (n /3).
The control group consisted of subjects without
clinical signs of cardiovascular or any other inflam-
matory disease; absence of such disease in their
medical history was also checked during the inter-
view before blood collection. All patients and control
subject in this study were from one referral centre,
University Hospital Olomouc. The study was per-
formed with the approval of the Ethics committee of
this institution.
Determination of MCP-1 protein
MCP-1 protein levels in serum obtained from study
participants were measured using a solid-phase
sandwich enzyme-linked immunosorbent assay
(Hbt kit; Hycult Biotechnology, Uden, the Nether-
lands). Briefly, 100 ml of duplicated samples or
standards (human MCP-1) were incubated (1 h,
room temperature) in the wells pre-coated with
primary anti-human MCP-1 antibody. After washing,
biotinylated secondary anti-human MCP-1 antibody,
and subsequently streptavidin /peroxidase conju-
gate, were added (both reagents for 1 h). Finally,
tetramethylbenzidine substrate solution was applied
for 25 min and, after stopping the reactions by 2 M
sulfuric acid, the absorbance was measured at
450 nm. The data were evaluated with KIM-E soft-
ware; the detection limit of the MCP-1 assay was 6.0
pg/ml.
Statistical analysis
STAT100 (Biosoft, Ferguson, MO, USA) software was
used to calculate basic statistical parameters and to
perform the Mann /Whitney U-test to test for differ-
ences in chemokine protein levels between the PAD
and control groups as well for further subanalysis.
Spearman’s rank correlation was used to assess
the relationship between MCP-1 and markers of
lipid profile. P B/0.05 was considered statistically
significant.
Results
MCP-1 in patients with PAD and in control
subjects
Detectable levels of MCP-1 were found in all inves-
tigated (patient and control) serum samples. Chemo-
kine levels in the PAD group were elevated: in 16 of
19 patient samples (84%), MCP-1 concentrations
exceeded the median MCP-1 level of the control
group (Fig. 1). The difference was highly significant
(p /0.0001).
When investigating a possible relationship be-
tween serum MCP-1 serum levels and disease course
as defined by the degree of claudication symptoms,
the patients with less severe symptomatology (stages
2a  /2b; category I, n /13) and patients with advan-
cing disease (stages 2c  /3; category II, n /6) were
grouped together. A trend towards a decrease of
chemokine levels in patients with advancing disease
(category II) was observed: category I (median9 /
standard error of the mean [SEM]), 8289 /60 pg/ml;
category II, 6939 /105 pg/ml (p /0.05).
When we took into account the location of the
atherosclerotic process in carotid arteries and divided
patients accordingly, MCP levels were similar in
patients with and without carotid artery involvement:
without (n /10), 7219 /77 pg/ml; with (n /9),
7109 /108 pg/ml.
Effect of atherosclerosis risk factors on MCP-1
serum levels
In order to explore effects of the known risk factors
of atherosclerosis on serum MCP-1 levels in
PAD patients, we first investigated patients with/
without concomitant diabetes mellitus. PAD patients
with diabetes (D  /, n /4) tended to have higher
MCP-1 levels than patients without diabetes
(D /, n /15). However, due to the low number of
subjects, the difference did not attain significance;
FIG. 1. MCP-1 serum levels (pg/ml) in healthy controls (C,
n /36) and in patients with PAD (n /19). Open circles,
individual MCP-1 values in male subjects; ﬁlled circles,
chemokine values in female subjects; lines, median values.
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pg/ml (p /0.05).
By contrast, hypertension had no effect on MCP-1
serum levels: hypertensive patients, /140 mmHg
(median9 /SEM), 7269 /58 pg/ml; normotensive pa-
tients, 7009 /90 pg/ml.
We also did not find a relationship between
cigarette smoking and chemokine levels. Serum
MCP-1 in smokers (n /6) was not different from
that of non-smokers (n /13) (median9 /SEM [range]):
smokers, 7429 /156 pg/ml (370 /1320 pg/ml); non-
smokers, 7059 /73 pg/ml (375 /1220 pg/ml).
There was no relationship between age and MCP-1
serum levels (rs /0.04, p  /0.05).
Relationship between MCP-1 and markers of
lipid profile
To reveal whether MCP-1 levels in PAD patients are
related to markers of lipid profile, correlations were
tested between MCP-1 and serum levels of four
markers in 18 patients (in one patient, complete
data were not available). Significant association was
observed between MCP-1 serum levels and serum
cholesterol (Fig. 2A), serum low-density lipoprotein
(LDL) (Fig. 2B), and also serum triglycerides. No
association was found between MCP-1 and serum
high-density lipoprotein (rs /0.103, p /0.05).
Twelve patients have been receiving hypolipidae-
mic treatment (T  /). However, this had virtually no
effect on MCP-1 serum levels (compared with the
subjects without treatment, (T /): T /, 7219 /129 pg/
ml; T  /, 6989 /78 pg/ml.
Discussion
Accumulation of mononuclear cells in the arterial
intima of patients with atherosclerosis is believed to
result from interplay between the trigger factors (e.g.
oxidized LDL) and the cell adhesion molecules,
chemokines and chemokine receptors.
1 In the pre-
sent study we have concentrated on a ‘candidate’ for
monocyte attraction, the chemokine MCP-1 (CC
chemokine ligand 2), in a specific form of athero-
sclerosis */ PAD. We demonstrate here that this CC
chemokine is elevated in circulation of patients with
PAD. The data also indicate that MCP-1 is more
elevated in serum of patients with earlier disease
stages and may be associated with the presence of
diabetes. Furthermore, chemokine levels detected in
our PAD patients correlated with serum cholesterol,
triglycerides and LDL but not with high-density
lipoprotein.
MCP-1 expression has been extensively studied in
cardiovascular disease but all studies have been
performed either in patients with typical ischaemic
heart disease or in hypertensive patients,
10 13 and
also in patients with myocarditis.
14 However, except
for a recent report by Matsui et al.
15 there have been
no further data on MCP-1 expression in PAD.
Importantly, the results of small study by Matsui et
al.
15 are in line with our findings: in their group of
eight Japanese patients with peripheral arterial ob-
structive disease, an elevation of MCP-1 was ob-
served.
15 The relative paucity of published data on
MCP-1 in PAD is, therefore, our main reason for
reporting the results of our pilot study despite the
number of enrolled patients not being high. It is
indeed possible that many interesting differences in
our patient subgroups will be presented differently if
more patients are available, and therefore continua-
tion of investigations of MCP-1 in PAD in our
laboratory, and namely in other centres, is warranted.
Elevation of MCP-1 in PAD patients fits into the
concept of promigratory and activating effects of this
chemokine on monocytes */ key cells of the early
inflammatory process of the arterial wall.
16 In this
context, it is interesting to note that MCP-1 levels
were highest in serum of the patients with less severe
symptomatology (i.e. earlier disease stages) and they
decreased with progressing disease. In our opinion,
this finding should be explored further to provide
rationale basis for possible inclusion of monitoring
MCP-1 serum levels into the algorhythm of manage-
FIG. 2. Relationship between serum MCP-1 and serum
cholesterol (A) or LDL (B). Circles, individual values of 18
patients. p values are based on the values of the Spearman
correlation coefﬁcient.
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possible clinical utilisation of MCP-1 as a surrogate
marker of atherosclerotic inflammation is supported
by finding that parenteral administration of prosta-
glandin E1 appeared to decrease circulating MCP-1
levels in eight patients with PAD.
15 Suppression of
the chemokine level by drugs, which is known to
produce clinical benefit in PAD patients, is in line
with the concept of MCP-1 involvement in the disease
pathobiological mechanism.
In our PAD patients, MCP-1 levels were related to
the markers of lipid metabolism (LDL, cholesterol,
triglycerides). The same association has been re-
ported in previous studies of patients with hyperten-
sive disease.
6 This confirms that the relationship
between the chemokine and lipids is a general
feature of atherosclerosis irrespective of its form
and/or localisation. This finding is also in agreement
with known in vitro observations that endothelial
cells secrete MCP-1 in response to oxidation of
LDL.
17,18
One may argue that we are reporting already
known associations between MCP-1 and coronary
artery disease. This is, however, not the case. When
chemokine protein levels observed in our PAD
patients were compared with data recorded recently
in our group of patients with coronary artery disease,
MCP-1 protein was higher in PAD than in coronary
atherosclerosis. This finding is in agreement with a
report that PAD contributes to increase the inflam-
matory status in subjects with atherosclerosis.
19
Also, an argument may arise that practical utilisa-
tion of MCP-1 measurements may be hampered due
to a gender effect on MCP-1: there was an isolated
report of increased MCP-1 levels in men compared
with women.
20 However, in our study there was
predominance of men in both the control and the
patient groups, and therefore a bias in our data and
their interpretation is not probable. Furthermore, no
gender effect on chemokine levels was apparent in
our control group and the MCP-1 value detected in
only one female was close to the median value of our
patient group (Fig. 1). Despite the male sex generally
being considered a risk factor for PAD,
8 in a recent
study of early-onset peripheral arterial occlusive
disease more than one-half of patients were wo-
men.
21 Importantly, the Rotterdam study, a popula-
tion-based analysis of nearly 8000 patients, revealed
that 17% of men and 21% of women aged 55 years
and older had PAD.
22 Future studies of the predictive
value of the MCP-1 assay should therefore include
equally men and women.
The present study, similar to other investigations of
blood markers in PAD,
19,23 exploited the standard
method of drawing blood samples from the cubital
vein irrespective of the location of claudication
symptoms. Given the mechanism of the inflammatory
cell recruitment by a gradient between systemic and
local chemokine concentrations,
1,24 it would be
interesting to investigate whether differences occur
between chemokine levels in blood samples taken
from the contralateral arm and/or leg.
In conclusion, the findings of this pilot study
extend previous observations of the MCP-1 role in
inflammatory processes associated with atherosclero-
sis also to PAD. Further work is, however, necessary
to define the MCP-1 relationship with the disease
development more precisely and also to provide a
definite answer to the question of whether measure-
ments of this chemokine may be exploited for follow-
up of patients with PAD.
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